Drug Discovery World

JUNE 14, 2023

We are a cell therapy company that uses a very specific receptor to engineer T cells and administer these engineered T cells back to solid tumour patients. We consider ourselves a next-generation engineered cell therapy company. There are a lot of successes that have been achieved with CAR T therapies.

Research 52

Research Engineer In-Vivo Production 52

Drug Discovery World

MAY 22, 2023

Ryan Leahy , a science communication expert in cell and gene therapy, at Phacilitate, says there is a lot to celebrate but also much to assess, question and challenge in this sector. But are these price tags a barrier to access? million per dose.

Gene Therapy 52

Gene Therapy Gene Drugs Contamination 52

pharmaphorum

JULY 25, 2022

The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for multiple myeloma , joining a growing group of BCMA-targeted therapies for the blood cancer.

Antibody 52

Antibody Medicine Drugs Trials 52

Delveinsight

FEBRUARY 9, 2021

Breyanzi, BMS’ Blood Cancer CAR-T Therapy Receives FDA Nod. As per the company, their one-time CAR-T cell therapy will be crucial in clinical practice in relapsed or refractory large B-cell lymphoma cases. Ukoniq’s approval was backed by Phase 2 UNITY-NHL Trial (NCT02793583).

FDA Approval 52

FDA Approval Marketing Research Protein 52

pharmaphorum

JANUARY 11, 2021

While bluebird has conducted pioneering work in gene therapy for blood disorders and in cancer cell therapy, products have been delayed by issues with filing data for the FDA. million price tag. The post bluebird bio to split into oncology and gene therapy specialists appeared first on.

Gene Therapy 59

Gene Therapy Gene Genetic Disease Manufacturing 59

pharmaphorum

FEBRUARY 22, 2021

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. . million in Europe.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. There are several different types of immunotherapies, including chemical inhibitors, cell-based therapies (i.e. chimeric receptor antigen [CAR] T cell) immune modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

pharmaphorum

MARCH 27, 2022

Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU the next few weeks, after getting a green light from the EMA’s human medicines committee. In the US, Abecma has a list price of around $420,00, while J&J has set its therapy a little higher at $465,000.

Antibody 96

Antibody Clinical Trials Clinical Trials Sales 96

pharmaphorum

NOVEMBER 16, 2022

The advancements made in drug development over the last decade have seen the arrival of a number of treatments that offer one-time cures and more effective therapies for conditions in smaller patient populations. However, alongside this progress, Ben Hargreaves finds that there is also a conundrum over how to price these therapies.

Gene Therapy 130

Gene Therapy Gene Marketing Development 130

Drug Discovery World

NOVEMBER 9, 2023

Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’. Troy Lionberger, PhD, Senior Vice President, Business Development, Bruker, on: ‘Accelerating functional TCR discovery by phenotyping thousands of live, single T cells in two days’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 13, 2023

Thereafter, the following presentations will take place: Bertolt Kreft, PhD, CSO, Bright Peak Therapeutics, on: ‘PD1-IL18 IC (BPT567) — A first-in-class and highly potent immunocytokine specifically targeting of PD-1+/IL18R+/CD8+ T effector cells enriched in the tumour microenvironment’.

Protein 59

Protein Antibody Engineer Scientist 59

Roots Analysis

AUGUST 28, 2022

Furthermore, several live cell imaging and non-destructive fluorescence histological methods measure limited number of biomarkers at a time and the tags introduced may interfere with the natural function of genes and proteins. For more details on this emerging domain, check out the following report : SPATIAL GENOMICS MARKET. Web: [link].

Genome 52

Genome Genomics RNA Genome Project 52

pharmaphorum

FEBRUARY 26, 2021

However, it wasn’t until 1959 – 73 years and two major acquisitions later – that J&J developed its significant presence in the pharmaceutical industry. The company has many interesting drugs in its pipeline, including a CAR-T therapy developed in partnership with Legend Biotech. Where it all began.

Sales 124

Sales Production Pharma Companies Marketing 124